AML by genetics: favourable, intermediate and adverse risk
- Foundations
Two people with the same-looking AML can have very different futures. The genes in the blasts decide who chemotherapy can cure and who needs a transplant.
What it is
Acute myeloid leukaemia is now classified and risk-graded by the chromosome changes and gene mutations of its blasts. International risk systems (the European LeukemiaNet scheme is the most used) sort patients into favourable, intermediate and adverse groups. The group predicts the chance of remission and relapse, decides whether a fit patient in first remission is consolidated with chemotherapy or sent to allogeneic stem cell transplant, and points to targeted drugs for FLT3, IDH1 or IDH2 mutations. Some genetic changes define AML on their own, whatever the blast count.
What to know
- Favourable: t(8;21) RUNX1::RUNX1T1 and inv(16) or t(16;16) CBFB::MYH11 (the core-binding factor leukaemias), NPM1 mutation without FLT3-ITD, and in-frame CEBPA mutations.
- Intermediate: NPM1 with FLT3-ITD, FLT3-ITD without NPM1, t(9;11), and lesions not classed as favourable or adverse.
- Adverse: complex or monosomal karyotype, loss of chromosome 5 or 7 or of 5q, 17p or TP53 changes, inv(3) or t(3;3), t(6;9), most KMT2A (11q23) rearrangements, BCR::ABL1, and myelodysplasia-related gene mutations such as ASXL1, RUNX1 and splicing genes.
- Acute promyelocytic leukaemia, PML::RARA from t(15;17), is handled separately: it is an emergency and among the most curable leukaemias.
- AML after chemotherapy or radiotherapy (therapy-related) or after MDS usually carries adverse genetics; prior alkylator exposure tends to damage chromosomes 5 and 7, topoisomerase II inhibitors tend to cause KMT2A rearrangements.
- Actionable mutations change the first treatment: FLT3 inhibitors with induction for FLT3-mutated AML, IDH inhibitors for IDH1 or IDH2, and an anti-CD33 antibody–drug conjugate in core-binding factor AML.
Step by step
- Send marrow for karyotype, FISH and a rapid gene panel (FLT3, NPM1, CEBPA, IDH1, IDH2, TP53) before induction starts.
- Exclude APL at once with PML::RARA testing and start all-trans retinoic acid on suspicion.
- Add the results within days: FLT3 status can change the induction combination.
- Assign the risk group and look for an HLA-matched donor early in intermediate and adverse groups.
- After induction, measure residual disease by flow cytometry or a molecular marker such as NPM1.
- Favourable with clearing MRD: chemotherapy consolidation; adverse, or persistent MRD: allogeneic transplant in fit patients.
The three risk groups and what they change
| Feature | Favourable | Intermediate | Adverse |
|---|---|---|---|
| Typical lesions | t(8;21), inv(16), NPM1 without FLT3-ITD, in-frame CEBPA | NPM1 with FLT3-ITD, FLT3-ITD alone, t(9;11), normal karyotype without risk genes | Complex karyotype, −5/5q−, −7, TP53, inv(3), t(6;9), KMT2A, ASXL1, RUNX1 |
| Typical patient | Younger adult, de novo AML | Any age | Older adult, AML after MDS or after cancer treatment |
| Response to induction | High remission rate | Moderate | Lower remission rate, frequent early relapse |
| First-remission plan in a fit patient | Chemotherapy consolidation; transplant only if MRD persists | Transplant often, weighed with donor and MRD | Allogeneic transplant if fit |
| Added targeted option | Anti-CD33 conjugate in core-binding factor AML | FLT3 inhibitor if FLT3 mutated | Clinical trials; venetoclax combinations in unfit patients |
How it shows in the patient
- Gum swelling and skin infiltrates suggest a monocytic AML, which often carries NPM1 or KMT2A changes, but only the genetic test assigns the risk.
- Patients with a previous cancer treated with chemotherapy who develop cytopenias years later should be asked about it: therapy-related AML changes the risk group.
- A family history of cytopenias, MDS or AML at a young age, or the same mutation (such as RUNX1, CEBPA or DDX41) in a sibling donor, suggests an inherited predisposition and changes donor choice.
- Older or frail patients with adverse genetics may still benefit from lower-intensity therapy; risk informs, it does not on its own decide whether to treat.
How to use it in practice
- Marrow aspirate for morphology, flow cytometry, conventional karyotype and FISH, plus a myeloid gene panel; repeat sampling if the karyotype fails.
- Rapid FLT3 and NPM1 results are the ones that can change induction in the first days.
- PML::RARA by FISH or PCR in every new AML with bleeding, DIC or hypergranular promyelocytes.
- HLA typing of the patient and siblings at diagnosis in intermediate or adverse risk.
- MRD after induction and consolidation (flow cytometry, NPM1 or core-binding factor transcripts) refines the risk group.
Common traps
- Waiting for the full karyotype before starting APL treatment: all-trans retinoic acid starts on suspicion because early bleeding death is the threat
- Calling every normal-karyotype AML intermediate risk: NPM1 without FLT3-ITD is favourable, and TP53 or ASXL1 make it adverse
- Assuming a favourable translocation guarantees a cure: KIT mutations, a high white count or persistent MRD can still push the patient towards transplant
- Testing a sibling donor without asking about inherited mutations: a donor carrying the same germline variant can pass on the risk
- Ignoring previous chemotherapy in the history: therapy-related AML usually means adverse genetics
Test yourself
Think of the answer, then tap the question to see it.
A 45-year-old with AML has a normal karyotype, an NPM1 mutation and no FLT3-ITD; MRD clears after induction. Which consolidation is usually chosen, and why?
Chemotherapy consolidation: this is favourable-risk AML that chemotherapy alone often cures, so the risks of an allogeneic transplant are not usually justified.
A 60-year-old treated for breast cancer five years ago now has AML with loss of chromosome 7 and a complex karyotype. Which risk group is this, and what does it mean for a fit patient?
Adverse (therapy-related, complex karyotype, −7); in a fit patient, allogeneic transplant in first remission is the plan because chemotherapy alone rarely holds it.
Why is the FLT3 result wanted within the first days of AML induction?
A FLT3 mutation adds a FLT3 inhibitor to induction chemotherapy and affects transplant planning, so a late result loses the chance to change the first treatment.
Which AML is started on all-trans retinoic acid before the genetic confirmation, and why?
Acute promyelocytic leukaemia: it causes early death from bleeding and DIC, and retinoic acid corrects the coagulopathy quickly, so waiting for confirmation costs lives.
Elsewhere in DurgiPedia
- Acute myeloid leukaemia
- Acute promyelocytic leukaemia
- Myelodysplastic neoplasms
- Genetic tests: what each one finds
- Marrow aspirate and biopsy: cellularity and the M:E ratio
- Haematopoietic stem cell transplant: the immunology
Connections
Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.
Sources: Acute Myeloid Leukemia (StatPearls (NCBI Bookshelf), 2024); Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version (National Cancer Institute, 2025); Core binding factor acute myeloid leukemia: MedlinePlus Genetics (MedlinePlus, US National Library of Medicine, 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
